Global Search | Novartis

Hide Filters

Showing 1233 results

Press Release / Oct 03, 2016

Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey

Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment[1]* Majority (84%) face…
Press Release / Oct 01, 2016

Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
Press Release / Sep 28, 2016

Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine

ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
Press Release / Sep 28, 2016

Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges

Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
Press Release / Sep 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions

Ilaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
Press Release / Sep 23, 2016

Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients

In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
Press Release / Sep 21, 2016

Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
Press Release / Sep 19, 2016

Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
Press Release / Sep 17, 2016

Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients

EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
Press Release / Sep 16, 2016

New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years

ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…